Leading with Parkinson’s Disease
There are 1 million people suffering with Parkinson’s in the U.S., and approximately 10 million suffering globally. Parkinson’s is a complex chronic, progressive, neurodegenerative disease with no cure. It continues to have a myriad of significant unmet needs, and patients suffer from – motor symptoms like tremor, dyskinesia, bradykinesia, dystonia, postural instability to name a few, but also non-motor symptoms like anxiety, depression, sleep disorders, pain and psychosis.
Non-motor symptoms can often be more detrimental to patients’ overall well-being and quality of life. These non-motor symptoms can be related to Parkinson’s itself, or from the medications used to treat it. For non-motor symptom management, pharmacotherapy selection can be based on considerations of safety and tolerability, and none of the drugs have shown clear difference in controlling non-motor symptoms in Parkinson’s Disease specific populations.
To address patient’s needs, Pike is developing proprietary transdermal CBD technology that can provide continuous treatment delivery over a 7 day period. This would be the first Parkinson’s specific therapy targeted to treat multiple non-motor symptoms and motor symptoms.
